Evidence map›Paper›PMID 25073857›Full record

Trial reportEuropean journal of preventive cardiology2016

Differential effects of insulin sensitization and insulin provision treatment strategies on concentrations of circulating adipokines in patients with diabetes and coronary artery disease in the BARI 2D trial.

Robert Wolk, Marnie Bertolet, Maria M Brooks, Richard E Pratley, Burton E Sobel, Robert L Frye, Prachi Singh, Andrew D Calvin, Martin K Rutter, Arshag D Mooradian and 2 more

Abstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of preventive cardiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Robert WolkDivision of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, USA Pfizer Global Research & Development, Pfizer Inc., Groton, USA Robert.Wolk@pfizer.com.
Marnie BertoletUniversity of Pittsburgh, USA.
Maria M BrooksUniversity of Pittsburgh, USA.
Richard E PratleyFlorida Hospital Diabetes and Translational Research Institutes, Orlando, USA.
Burton E SobelUniversity of Vermont, Burlington, USA.
Robert L FryeDivision of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, USA.
Prachi SinghDivision of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, USA.
Andrew D CalvinDivision of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, USA.
Martin K RutterEndocrinology and Diabetes Research Group, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, UK Manchester Diabetes Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, UK.
Arshag D MooradianDivision of Endocrinology, Diabetes and Metabolism, College of Medicine-Jacksonville, University of Florida, USA.
Virend K SomersDivision of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, USA.
BARI 2D study group

Funding

BARI II:Foreign RecruitmentU01HL061744 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KELSEY, SHERYL F · 2000 to 2009
$55.4M
Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
BARI II - FIBRINOLYSIS AND COAGULATION COREU01HL063804 · NHLBI · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI SOBEL, BURTON E · 2000 to 2006
$3.8M
ECONOMIC OUTCOMES OF TREATMENT STRATEGIES IN BAR1-2U01HL061748 · NHLBI · STANFORD UNIVERSITY · PI HLATKY, MARK A. · 2000 to 2006
$2.6M
BARI II GRANT PROPOSAL FOR ECG CORE LABORATORYU01HL061746 · NHLBI · SAINT LOUIS UNIVERSITY · PI CHAITMAN, BERNARD R · 2000 to 2008
$1.6M
Adipokines and Cardiovascular Disease in DiabetesR01HL087214 · NHLBI · MAYO CLINIC ROCHESTER · PI SOMERS, VIREND K · 2009 to 2010
$1.2M
Treatment and Risk Factor Determinants of Cardiovascular Outcomes in BARI 2DR21HL121495 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BROOKS, MARIA MORI · 2013 to 2014
$222k
NCATS NIH HHS UL1 TR000135NCATS NIH HHS UL1 TR001427NHLBI NIH HHS HL061744NHLBI NIH HHS R01 HL087214NHLBI NIH HHS R01HL087214NHLBI NIH HHS R21 HL121495NHLBI NIH HHS U01 HL061744NHLBI NIH HHS U01 HL061746NHLBI NIH HHS U01HL061746NHLBI NIH HHS U01 HL061748NHLBI NIH HHS U01HL061748NHLBI NIH HHS U01 HL063804NHLBI NIH HHS U01HL063804
6 · The paper itself

Abstract

aimsTo determine the effects of insulin sensitization (IS) and insulin provision (IP) treatment strategies on adipokines associated with cardiovascular disease in patients with type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D). METHODS AND

resultsChanges in adipokine levels were compared in patients with type 2 diabetes mellitus and coronary artery disease randomized to IS (n = 1037) versus IP (n = 1019) treatment strategies in BARI 2D. Circulating concentrations of leptin, adiponectin, monocyte chemoattractant protein-1, tumor necrosis factor-alpha, interleukin 6 and C-reactive protein were evaluated at baseline and one year. IS and IP treatment strategies exerted significant (p < 0.0001) differential effects on: leptin (IS: 0.02% decrease, p = 0.01; IP: 13% increase, p < 0.0001); adiponectin (IS: 73% increase, p < 0.0001; IP: no change, p = 0.52); interleukin 6 (IS: 14% decrease, p < 0.0001; IP: no change, p = 0.68). Changes in monocyte chemoattractant protein-1 and tumor necrosis factor-alpha were not statistically different between groups. C-reactive protein decreased, but the effect was significantly greater in the IS group (-32%, p < 0.0001) than in the IP group (-5%, p = 0.0005).

conclusionThe IS and IP treatment strategies exerted divergent effects on adipokine and inflammatory profile in patients with type 2 diabetes mellitus and coronary artery disease. The IS treatment strategy-induced changes may be more favorable than the IP treatment strategy regarding cardiovascular pathophysiology.

Indexed as

Insulin ResistanceAdipokinesAgedBiomarkersBlood GlucoseCoronary Artery DiseaseDiabetes Mellitus, Type 2FemaleGlycated HemoglobinHumansHypoglycemic AgentsInflammation MediatorsInsulinMaleMiddle AgedTime FactorsAdipokinesBiomarkersBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInflammation MediatorsInsulinadipokinescoronary diseaseDiabetes mellitusrisk factors

Identifiers

PMID25073857
PMCPMC4385003

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.